Skip to main navigation Skip to search Skip to main content

Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial

  • Reinoud E Knops*
  • , Shari Pepplinkhuizen
  • , Peter Paul H M Delnoy
  • , Lucas V A Boersma
  • , Juergen Kuschyk
  • , Mikhael F El-Chami
  • , Hendrik Bonnemeier
  • , Elijah R Behr
  • , Tom F Brouwer
  • , Stefan Kaab
  • , Suneet Mittal
  • , Anne Floor B E Quast
  • , Willeke van der Stuijt
  • , Lonneke Smeding
  • , Jolien A de Veld
  • , Jan G P Tijssen
  • , Nick R Bijsterveld
  • , Sergio Richter
  • , Marc A Brouwer
  • , Joris R de Groot
  • Kirsten M Kooiman, Pier D Lambiase, Petr Neuzil, Kevin Vernooy, Marco Alings, Timothy R Betts, Frank A L E Bracke, Martin C Burke, Jonas S S G de Jong, David J Wright, Ward P J Jansen, Zachary I Whinnett, Peter Nordbeck, Michael Knaut, Berit T Philbert, Jurren M van Opstal, Alexandru B Chicos, Cornelis P Allaart, Alida E Borger van der Burg, Jose M Dizon, Marc A Miller, Dmitry Nemirovsky, Ralf Surber, Gaurav A Upadhyay, Raul Weiss, Anouk de Weger, Arthur A M Wilde, Louise R A Olde Nordkamp
*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: The subcutaneous ICD (S-ICD) is developed to overcome lead-related complications and systemic infections, inherent to transvenous ICD (TV-ICD) therapy. The PRAETORIAN trial demonstrated that the S-ICD is non-inferior to the TV-ICD with regard to the combined primary endpoint of inappropriate shocks and complications. This prespecified secondary analysis evaluates all complications in the PRAETORIAN trial.

METHODS: The PRAETORIAN trial is an international, multicenter, randomised trial in which 849 patients with an indication for ICD therapy were randomised to receive an SICD (N = 426) or TV-ICD (N = 423) and followed for a median of 49 months. Endpoints were device-related complications, lead-related complications, systemic infections and the need for invasive interventions.

RESULTS: Thirty-six device-related complications occurred in 31 patients in the S-ICD group of which bleedings were the most frequent. In the TV-ICD group 49 complications occurred in 44 patients of which lead-dysfunction was most frequent (HR 0.69; P =0.11). In both groups half of all complications were within 30 days after implantation. Lead-related complications and systemic infections occurred significantly less in the S-ICD group compared to the TV-ICD group (P <0.001, P =0.03 respectively). Significantly more complications required invasive interventions in the TV-ICD group compared to the S-ICD group (8.3% vs. 4.3%, HR 0.59; P =0.047).

CONCLUSIONS: This secondary analysis shows that, lead-related complications and systemic infections are more prevalent in the TV-ICD group compared to the S-ICD group. In addition, complications in the TV-ICD group were more severe as they required significantly more invasive interventions. This data contributes to shared decision making in clinical practice.

Original languageEnglish
Pages (from-to)4872-4883
Number of pages12
JournalEuropean Heart Journal
Volume43
Issue number47
Early online date28 Aug 2022
DOIs
Publication statusPublished - 14 Dec 2022

Fingerprint

Dive into the research topics of 'Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial'. Together they form a unique fingerprint.

Cite this